Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Prefilled Syringes Market worth $13.1 billion by 2030 driven by Rising Chronic…
Browse in-depth TOC on "Prefilled Syringes Market" Browse in-depth TOC on "Prefilled Syringes Market" 243 - Tables 59 - Figures 292 - Pages BD (US): Leader in Medical Technology and Drug Delivery Systems BD stands out as a prominent player in medical technology, specializing in the production and sale of medical devices, reagents, and instruments. The company's diverse portfolio includes syringes and pen needles, intravenous catheters, infusion pumps, automated medication...
PR Newswire
29/07/2024
Non-muscle Invasive Bladder Cancer Market to Reach US$ 21.1 Billion by 2034 with…
Non-muscle invasive bladder cancer (NMIBC) is referred to as cancer located in tissue lining the bladder's inner surface. The bladder muscle is not playing role over there. Bladder cancer is more prevalent in men as compared to women. It is also common with aging. It is generally seen in age group of 75-84. Non-muscle invasive bladder cancer (NMIBC) is referred to as cancer located in tissue lining the bladder's inner surface. The bladder muscle is not playing role over there. Bladder cancer…
PR Newswire
29/07/2024
SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA…
L'hôpital Avicenne, which serves approximately 500,000 patients annually across all areas of care, is a clinical, research, and teaching hospital, known for its expertise in oncology. L'hôpital Avicenne's clinical hematology department treats various hematological malignancies via 25 in-patient beds and outpatient care. L'hôpital Avicenne, which serves approximately 500,000 patients annually across all areas of care, is a clinical, research, and teaching hospital, known for its expertise in…
PR Newswire
29/07/2024
Veterinary Supplements Market to Reach US$ 15.2 Billion by 2031, Driven by…
Veterinary supplements are amongst the vital components of modern-day animal husbandry practices. They make provisions for essential vitamins, minerals, and the other nutrients that conventional feed sources fail to provide. Veterinary supplements are amongst the vital components of modern-day animal husbandry practices. They make provisions for essential vitamins, minerals, and the other nutrients that conventional feed sources fail to provide. As per 2020 report by FONA International Inc...
PR Newswire
29/07/2024
Biotech API Manufacturing Services Market to Reach US$ 73 Billion by 2031…
Extensive use of biologically active substances in the development of innovative and effective pharmaceutical drugs is contributing to the global biotech API manufacturing services market size, which is expected to register a CAGR of 7.1% from 2023 to 2031 to surpass US$ 73.0 Bn by 2031, according to Transparency Market Research (TMR), a leading global market research firm. Extensive use of biologically active substances in the development of innovative and effective pharmaceutical drugs is...
PR Newswire
29/07/2024
Study Showing Pathway to Significant Greenhouse Emissions Reductions In Medical…
WHAT: A new peer reviewed study to be released July 30, 2024, comparing the environmental footprint of an innovative prefilled injection device to widely used traditional glass syringe options. This groundbreaking study shows that greenhouse gas emissions can be reduced significantly by soon to be available blow-fill-seal (BFS) manufactured prefilled injectors. WHAT : A new peer reviewed study to be releasedJuly 30, 2024, comparing the environmental footprint of an innovative prefilled...
PR Newswire
29/07/2024
Buyback of Class B shares in Essity during week 30, 2024
The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
29/07/2024
HKBU develops new approach for accurate and efficient inspection of…
More accurate and efficient test in need More accurate and efficient test in need Sulfur treatment, including sulfur fumigation and the addition of sulfites, is a common preservation method employed in the food and Chinese herbal medicinal industries. However, excessive consumption of preservative sulfites in food and Chinese herbal medicinal products can lead to respiratory symptoms and compromised nutritional value and safety. Currently, sulfite test is the most commonly used...
PR Newswire
29/07/2024
IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's…
About IM Cannabis Corp. About IM Cannabis Corp. IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients inIsraelandGermany, two of the largest medical cannabis markets. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments,...
PR Newswire
29/07/2024
Endo Releases Annual Corporate Responsibility Report
The 2023 report details efforts and progress across four pillars. Here are select 2023 highlights: The 2023 report details efforts and progress across four pillars. Here are select 2023 highlights: Business Practices: Team: Customers: World: Read the full report atendo.com. About EndoEndo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver...
PR Newswire
29/07/2024
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 29 July 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…
Nasdaq GlobeNewswire
29/07/2024
EXPOSURE TO WILDFIRE SMOKE GREATLY RAISES RISK OF DEMENTIA DIAGNOSIS
Wildfire smoke, motor vehicles and factories all emit a type of air pollution called fine particulate matter (PM2.5). This is a microscopic mixture of solid and liquid droplets in the air that are 30 times smaller than the width of an average human hair. Researchers found that the risk of dementia diagnosis due to exposure to PM2.5 in wildfire smoke was notably stronger — even with less exposure — than the risk due to the other sources of PM2.5 air pollution. Exposure to non-wildfire PM2.5…
PR Newswire
29/07/2024
Tilray's Aphria RX Receives Cannabis Trading License in Germany, Significantly…
"This milestone of Aphria RX obtaining both its new cultivation license as well as its trading license further expands Tilray's leadership in medical cannabis research, cultivation, production and distribution in Germany and once again proves our commitment to be one of the most responsible, trusted and market leading cannabis companies in the world with a portfolio of innovative and high-quality products that address the needs of patients. We remain dedicated to advocating for…
Nasdaq GlobeNewswire
29/07/2024
Prescription Digital Therapeutics (PDT) Market Expected to Grow at a CAGR of…
Prescription Digital Therapeutics (PDT) represent a new category of medical treatments that utilize software applications to deliver therapeutic interventions under the supervision of healthcare providers. Prescription digital drugs are created by combining biology and technology. Artificial intelligence, various algorithms, and virtual reality were used in the creation of these therapeutic aids. Digital therapies, or prescription PDTs, are a relatively new class of medications. PDTs function as…
PR Newswire
29/07/2024
Hepatocyte Growth Factors (HGFs) Market to Reach USD 141 Million by 2034: Rising…
Hepatocyte growth factors (HGFs) are amongst the potent mitogens for hepatocytes and various other cells that include keratinocytes and melanocytes apart from epithelial and endothelial cells. HGFs are also ligands for receptors encoded by c-met proto-oncogene. Hepatocyte growth factors (HGFs) are amongst the potent mitogens for hepatocytes and various other cells that include keratinocytes and melanocytes apart from epithelial and endothelial cells. HGFs are also ligands for receptors…
PR Newswire
29/07/2024
AliveDx Receives IVDR CE Mark for Groundbreaking Microarray Immunoassay in…
The multiplex immunoassay microarray technology marks a significant advancement in diagnostics by enabling simultaneous testing for multiple conditions. This approach streamlines the identification process, simplifies laboratory workflows, and reduces the hands-on time required with singleplex methods. As a result, both laboratories and clinicians save valuable time and can detect and rule out various conditions more efficiently. For patients sensitized to multiple allergens (polysensitized)…
PR Newswire
29/07/2024
Nucleic Acid Aptamers Market to Reach USD 1.2 Billion by 2034: Unique…
Since their discovery in the 1990s, several attempts have been made to utilize aptamers as clinical agents for diseases such as AIDS and macular degeneration. It is important to note that the first aptamer-based therapeutic to receive U.S. FDA approval was Macugen (Pegaptanib), that acts as a selective antagonist of vascular endothelial growth factor (VEGF) and is indicated for the treatment of patients suffering from neovascular age-related macular degeneration. Since their discovery in the...
PR Newswire
29/07/2024
Invitation to Immunovia's Q2 presentation
Telephone numbers and webcastCall any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts. Telephone numbers and webcastCall any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts. Sweden : +46 (0)8 5051 0031United Kingdom : +44 (0) 207 107 06 13United States : +1 (1) 631 570 56 13 Link to the webcast: ...
PR Newswire
29/07/2024
Liposomal Supplements Market Anticipated to Achieve US$ 741.0 million Valuation…
Advancement of technology in the production of liposomes and encapsulation techniques are aspects which have increased the growth in the market. These new developments let one formulate stable, potent, and targeted supplements that are luring investments from new entrants as well as established companies in the nutraceutical sector. Advancement of technology in the production of liposomes and encapsulation techniques are aspects which have increased the growth in the market. These new...
PR Newswire
29/07/2024
CHMP adopts positive opinion recommending approval of new and expanded…
The CHMP positive opinion is based on the EFFISAYIL® 2 trial, which showed that no flares were observed after week 4 of SPEVIGO® administered subcutaneously. During the 48-week trial, an 84% reduction of the risk of GPP flares was observed.GPP is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin flares and systemic symptoms, such as fever, pain, and fatigue.SPEVIGO® is currently approved in 51 countries for treatment of GPP flares, and the CHMP opinion...
Nasdaq GlobeNewswire
29/07/2024
EssilorLuxottica announces launch of share buyback program
EssilorLuxottica announces launch of share buyback programParis, France (July 29, 2024 – 08:00 am CEST)– EssilorLuxottica announces the launch of its share buyback program reflecting the Group's confidence in its value creation and long-term prospects.With a view to implementing this share buyback program, EssilorLuxottica has granted a mandate to an investment services provider for the purchase of up to 4,000,000 EssilorLuxottica shares, depending on market conditions, over a period...
Nasdaq GlobeNewswire
29/07/2024
DBV Technologies to Report Second Quarter 2024 Financial Results and Business…
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, July 30 th, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update.Interested participants may access this call via the...
Nasdaq GlobeNewswire
29/07/2024
BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m…
BERGEN, Norway, July 29, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the independent Data and Safety Monitoring Board (DSMB) for BerGenBio's Phase 1b/2a BGBC016 study confirmed acceptable safety at the highest dose tested in the Phase 1b. As a result, the DSMB also recommended that under the study protocol, no additional patients will be required…
PR Newswire
29/07/2024
Roche closes acquisition of LumiraDx's Point of Care technology to expand access…
The acquisition of LumiraDx's Point of Care technology received all required antitrust and regulatory clearances.LumiraDx's transformative Point of Care solution will complement Roche's diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areas.By integrating LumiraDx, Roche will further its ambition to deliver decentralised solutions that expand global access to testing in primary care settings worldwide.Basel,...
Nasdaq GlobeNewswire
29/07/2024
Altri Comunicati
